US 11,707,437 B2
Topical formulations with resiniferatoxin nanoparticles and methods
Louis Premkumar, Springfield, IL (US); and Baskaran Thyagarajan, Laramie, WY (US)
Assigned to BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY, Springfield, IL (US); and UNIVERSITY OF WYOMING, Laramie, WY (US)
Filed by Board of Trustees of Southern Illinois University, Springfield, IL (US); and University of Wyoming, Laramie, WY (US)
Filed on Jul. 10, 2020, as Appl. No. 16/925,551.
Claims priority of provisional application 62/873,520, filed on Jul. 12, 2019.
Prior Publication US 2021/0007998 A1, Jan. 14, 2021
Int. Cl. A61K 9/51 (2006.01); A61K 31/35 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/36 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61P 25/02 (2006.01); A61K 9/70 (2006.01); A61K 47/44 (2017.01)
CPC A61K 9/5153 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/7015 (2013.01); A61K 31/35 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/36 (2013.01); A61K 47/44 (2013.01); A61P 25/02 (2018.01)] 14 Claims
OG exemplary drawing
 
1. A nanoparticle comprising resiniferatoxin (RTX) encapsulated in a poly(lactic-co-glycolic acid) (PLGA) polymer for topical application, the nanoparticle having a size in the range from 5 nm to 100 nm, wherein the nanoparticle penetrates the transdermal skin barrier and wherein resiniferatoxin is loaded in the nanoparticle in a concentration ranging from 100 femtomoles (fM) to one micromole (μM).